Thomas R DiRaimondo

Title: Thomas R DiRaimondo: Innovator in Tumor-Targeted Antibodies

Introduction

Thomas R DiRaimondo is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of biotechnology, particularly in the development of tumor-targeted antibodies. With a total of 6 patents, his work focuses on innovative methods to enhance cancer treatment.

Latest Patents

DiRaimondo's latest patents include compositions and methods related to tumor-activated antibodies targeting the epidermal growth factor receptor (EGFR) and effector cell antigens. One of his notable inventions involves multispecific antibodies that selectively bind to EGFR and effector cell antigens such as CD3. These innovations provide pharmaceutical compositions and nucleic acids, along with methods for their creation and discovery. Another patent focuses on redirecting T cells to cancers by utilizing antibodies that bind to tumor-associated antigens while simultaneously engaging effector cell antigens on T cells.

Career Highlights

Currently, Thomas R DiRaimondo is associated with Janux Therapeutics, Inc., where he continues to advance his research in cancer therapies. His work is pivotal in developing new strategies for immunotherapy, aiming to improve patient outcomes in oncology.

Collaborations

Throughout his career, DiRaimondo has collaborated with notable professionals in the field, including David Alan Campbell and Ramesh Bhatt. These partnerships have fostered a collaborative environment that enhances innovation and research in cancer treatment.

Conclusion

Thomas R DiRaimondo stands out as a key figure in the development of tumor-targeted therapies. His innovative patents and ongoing work at Janux Therapeutics, Inc. contribute significantly to the fight against cancer.